期刊文献+

匹伐他汀对急性冠状动脉综合征疗效及安全性研究 被引量:1

The study on the tissue effectiveness and safety of pitavastatin in patients with acute coronary syndrome
下载PDF
导出
摘要 目的观察急性冠状动脉综合征(acute coronary syndrome,ACS)患者接受匹伐他汀应治疗的安全性及疗效。方法 60例ACS患者,含20例非ST段抬高心肌梗死(NSTEMI)服用1周匹伐他汀(力清之,4 mg/次,1次/d),观察其调脂疗效。同时比较NSTEMI患者服用匹伐他汀与阿托代他汀后PCI手术即刻疗效。结果 60例患者服用1周匹伐他汀,胆固醇(total cholesterol,TC)及低密度脂蛋白(low density lipoprotein,LDL)明显降低,且无肝肾功能及肌肉的损害;NSTEMI患者服用匹伐他汀与阿托代他汀PCI术后近期效果无显著差异,且匹伐他汀临床副作用明显小于阿托代他汀。结论对于ACS患者,无论是否行PCI手术治疗,服用1周匹伐他汀(4 mg/次,1次/d)强化治疗是安全有效的。 Objective To observe the effectiveness and safety by pitavastatin in patients with acute coronary syndrome(ACS). Methods In this study, we administered pitavastatin (4 mg/d) for one week in 60 patients with ACS (20 NSTEMI) and then investigated the effectiveness. Patients with NSTEMI PCI were randomly assigned to two groups with open-label treatment with pitavastatin or atorvastatin. Results 60 patients treated with pitavastatin for one week lowered LDL-C and TC clearly, no damage to muscle, liver and kidney functions, and the same PCI result was detected in the group from pitavastatin to atorvastatin, the adverse effect was significantly reduced with pitavastatin treatment compared with that with atorvastatin. Conclusion Accordingly, it was demonstrated that pitavastatin (4 mg daily) strengthened treatment is useful for the patients with acute coronary syndrome whenever the patients for PCI or not.
出处 《同济大学学报(医学版)》 CAS 2011年第4期73-76,共4页 Journal of Tongji University(Medical Science)
关键词 匹伐他汀 急性冠脉综合征 安全性 pitavastatin acute coronary syndrome safety
  • 相关文献

参考文献12

  • 1中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5223
  • 2Fukutomi T,Takeda Y,Suzuki S,et al.High density lipoprotein cholesterol and apolipoprotein A-I are persistently elevated during long-term treatment with pitavastatin,a new HMG-CoA reductase inhibitor[J].lnt JCardiol,2010,141 (3):320-322.
  • 3Sasaki J,Ikeda Y,Kuribayashi T,et al.A 52-week,randomized,openlabel,parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance[J].Clin Ther,2008,30(6):1089-1101.
  • 4Yoshika M,Komiyama Y,Masuda M,et al.Pitavastatin further decreases serum high-sensitive C-reactive protein levels in hypertensive patients with hypercholesterolemia treated with angiotensin Ⅱ,type-1 receptor antagonists[J].Exp Hypertens,2010,32(6):341-346.
  • 5Takemoto M,Liao - Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors[J].Artedoscler Thromb Vasc Biol,2001,21(11):1712-1719.
  • 6Hiraoka M,Nitta N,Nagai M,et al.MCP-1-induced enhancement of THP-1 adhesion to vascular endothelium was modulated by HMG-CoA reductase inhibitor through RhoA GTPase-,but not ERK1/2-dependent pathway[J].Life Sci,2004,75(11):1333-1341.
  • 7田云静,杨明,王青,韩凌,尹朝霞,高亢,赵燕,岑强,孙一光,李晓红.普罗布考与阿托伐他汀联合对急性冠状动脉综合征氧化低密度脂蛋白和炎症因子的影响[J].中国循环杂志,2008,23(6):426-429. 被引量:2
  • 8郭晓碧.急性冠状动脉综合征患者基线C反应蛋白和低密度脂蛋白水平对其急性期预后的意义[J].中国心血管病研究,2010,8(1):19-22. 被引量:6
  • 9Kaneyuki U,Ueda S,Yamagishi S,et al.Pitavastatin inhibits lysophosphatidic acid-induced proliferation and monocyte chemoattractant protein-1 expression in aortic smooth muscle cells by suppressing Rac-1-mediated reactive oxygen species generation[J].Vascul Pharmacol,2007,46(4):286-292.
  • 10Kimura K,Shimano H,Yokote K,et al.Effects of pitavastatin(LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease.Sub-analysis of the LIVALO Effectiveness and Safety (LIVES) Study[J].J Atheroscler Thromb,2010,17(6):601-619.

二级参考文献188

共引文献5230

同被引文献2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部